Señales en vivo de GLSI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers...

Stats
Volumen de hoy	27 889.00
Volumen promedio	52 203.00
Capitalización de mercado	168.96M
EPS	$0 ( 2024-03-29 )
Próxima fecha de ganancias	( $-0.200 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.01
ATR14	$0.170 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Snehal	Buy	3 000	Common Stock
2024-03-22	Patel Snehal	Buy	2 500	Common Stock
2024-03-20	Patel Snehal	Buy	1 500	Common Stock
2024-03-05	Patel Snehal	Buy	30 500	Common Stock
2024-03-04	Patel Snehal	Buy	4 100	Common Stock

INSIDER POWER
100.00
Last 96 transactions
Buy: 968 139 \| Sell: 271 338

Volumen Correlación

Largo: -0.13 (neutral)

Corto: 0.94 (very strong)

Signal:(56.048) Expect same movement, but be aware

Greenwich LifeSciences, Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Greenwich LifeSciences, Correlación - Moneda/Commodity

0.06
( neutral )

0.13
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.16
( neutral )

0.46
( neutral )

Greenwich LifeSciences, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-3 612.00 (0.00 %)
EPS:	$-0.690

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-3 612.00 (0.00 %)
EPS:	$-0.590

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Greenwich LifeSciences,

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.